Anti-inflammatory Effects of Rivaroxaban Versus Dabigatran
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.
Also called NCT02331602
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 200 participants
- Registry
-
NCT02331602
-
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Japan
- Registry status
- Unknown status
Technical summary
Registry record NCT02331602. Randomized; no masking; primary purpose treatment. Start 2013-07 (registry gives no type); primary completion 2015-10 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Anti-inflammatory Effects of Rivaroxaban Versus Dabigatran
- Acronym
- RIVAL-AF
- Condition
- Atrial Fibrillation
- Intervention (Drug)
- Rivaroxaban
- Intervention (Drug)
- Dabigatran
- Lead sponsor
- Yokohama City University Medical Center
- Collaborator
- Yokohama City University
Record details
- Record id
cardio:ct-nct02331602- Content hash
6911c9384a4faaa45251ecac541f68bcec34fe708fa13eb87d9d09060dc96e27